Karuna Therapeutics is a Massachusetts-based developer of drugs for the treatment of schizophrenia.
Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 9, 2022 | Post-IPO Equity | $750M | — | — | — | Detail |
Mar 1, 2021 | Post-IPO Equity | $250M | — | — | — | Detail |
Jun 27, 2019 | IPO | $89.24M | — | — | — | Detail |
Mar 18, 2019 | Series B | $68M | 10 | ARCH Venture Partners | — | Detail |
Aug 2, 2018 | Series A | $42M | 4 | ARCH Venture Partners | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
ARCH Venture Partners | Yes | Series B |
Alexandria Venture Investments | — | Series B |
Eventide | — | Series B |
Fidelity Management and Research Company | — | Series B |
Partner Fund Management | — | Series B |
Pivotal bioVenture Partners | — | Series B |
PureTech Health | — | Series B |
Sands Capital Ventures | — | Series B |
Sofinnova Investments | — | Series B |
Wellcome Trust | — | Series B |